Evidence mapPaperPMID 37781463Full record

ArticleDiabetology international2023

Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.

Yukiko Onishi, Shinichiro Shirabe, Kosei Eguchi, Keiji Nishijima, Toshihiro Sato, Hiroaki Seino

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Diabetology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03786406 completednot on this map

A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes in Selected Countries in Europe

TypeobservationalSponsorNovo Nordisk A/SRan2018 to 2019Enrolled2,275ConditionsDiabetes Mellitus, Type 2ArmsNo treatment given
NCT03811288 completednot on this map

A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes - an International Observation

TypeobservationalSponsorNovo Nordisk A/SRan2018 to 2019Enrolled7,548ConditionsDiabetes Mellitus, Type 2ArmsNo treatment given
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yukiko OnishiThe Institute of Medical Science, Asahi Life Foundation, 2-2-6 Nihonbashibakurocho, Chuo-ku, Tokyo, 103-0002 Japan.ORCID 0000-0003-1180-5982
Shinichiro ShirabeHEC Science Clinic, Yokohama, Japan.
Kosei EguchiNovo Nordisk Pharma Ltd., Tokyo, Japan.
Keiji NishijimaNovo Nordisk Pharma Ltd., Tokyo, Japan.
Toshihiro SatoNovo Nordisk Pharma Ltd., Tokyo, Japan.
Hiroaki SeinoSeino Internal Medicine Clinic, Fukushima, Japan.
The Institute of Medical Science, Asahi Life Foundation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The CAPTURE study estimated the global prevalence of established cardiovascular disease (CVD) and characterized the usage of glucose-lowering agents (GLAs) in adults with type 2 diabetes (T2D) across 13 countries. The purpose of this secondary analysis of data from the Japanese sites within CAPTURE (NCT03786406, NCT03811288) was to provide data about medication usage stratified by CVD status among Japanese participants with T2D. Materials and methods: Data on GLA usage (including those with proven cardiovascular [CV] benefits) in Japanese participants with T2D managed in clinics or hospitals were collected and stratified by CVD subgroups. Results: There were 800 Japanese participants in the CAPTURE study ( Conclusion: This analysis of the CAPTURE study provided a comprehensive overview of prescription patterns for the treatment of T2D in Japan. Use of GLAs with proven CV benefit was low, even in participants with established CVD, which was comparable to the findings from the global cohort. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-023-00638-w.

Indexed as

Diabetes mellitus, type 2Glucagon-like peptide-1Sodium-glucose cotransporter-2 inhibitors

Identifiers

PMID37781463
PMCPMC10533472
OpenAlexW4380607823

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.